An observational study in Lung Cancer, sponsored by China-Japan Friendship Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-01-31.
Sponsored by China-Japan Friendship Hospital · Observational
In the past few years, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNAs, autoantibodies, and T-cell receptor repertoire are new biomarkers of liquid biopsy in cancer, which has been demonstrated to have a great value in diagnostics, treatment evaluation, and prognosis prediction. However, most of previous data were based on late stage tumor patients. This study plans to utilize the minimally invasive method to detect the changes of numbers of CTCs, ctDNA hot spot mutations and methylation signals, microRNAs, autoantibodies, and T-cell receptor repertoire in early stage lung cancer patients before and after pulmonary nodule biopsy, during therapeutic and follow-up periods, in order to evaluate the clinical values of above tumor-related biomarkers.
Patients with pulmonary nodules (single or multiple) by CT scans.
Exclusion Criteria:
Death or survival
Death or survival
Time frame: Baseline and every three- or six-month follow-up within two years for each patient.
Disease progress
Complete Response(CR), Partial Response(PR), Stable Disease(SD), Progressive Disease(PD)
Time frame: Baseline and every three- or six-month follow-up within two years for each patient.
Reasons of study termination
Complete the study, Lost to follow-up, Withdrawal of informed consent, Terminated by the investigator, Severe adverse event(SAE).
Time frame: Baseline and every three- or six-month follow-up within two years for each patient.
This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China-Japan Friendship Hospital